<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04145310</url>
  </required_header>
  <id_info>
    <org_study_id>BOL-P-11</org_study_id>
    <nct_id>NCT04145310</nct_id>
  </id_info>
  <brief_title>BOL-DP-o-04 in Patients With Low Back Pain and Sciatica</brief_title>
  <official_title>A Prospective, Single-Center, Double-Blind, Placebo-Controlled Trial of BOL-DP-o-04 in Patients With Low Back Pain and Sciatica</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Breath of Life International Pharma Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Breath of Life International Pharma Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is aimed to evaluate the pain-relieving effect of BOL-DP-o-04, in addition to SOC,
      on Low Back Pain and Sciatica.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Prospective, Single-Center, Double-Blind, Placebo-Controlled Trial of BOL-DP-o-04 in
      Patients with Low Back Pain and Sciatica. The study is aimed to evaluate the pain-relieving
      effect of BOL-DP-o-04, in addition to SOC, on Low Back Pain and Sciatica.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 27, 2018</start_date>
  <completion_date type="Anticipated">November 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 15, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Oswestry Disability Index</measure>
    <time_frame>Baseline to Day 114</time_frame>
    <description>Change in the Oswestry Disability Index. The questionnaire is composed by 10 sections Each section can be scored 0 to 5, 5 being the worst case. The score is calculated by summing the different sections and then doubling the total. Maximum score is 100.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Brief Pain Index</measure>
    <time_frame>Baseline to Day 100</time_frame>
    <description>Change in the Brief Pain Index relative to baseline. The Brief Pain Inventory rapidly assesses the severity of pain and its impact on functioning</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Form (SF12) Mental</measure>
    <time_frame>Screening to Day 100</time_frame>
    <description>Change in Short Form (SF12) Mental Composite Score.The SF-12 consists of a subset of 12 items that measure eight health domains to assess physical and mental health</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pittsburgh Sleep Quality Index</measure>
    <time_frame>Screening to Day 100</time_frame>
    <description>Change in Pittsburgh Sleep Quality Index. The Pittsburgh Sleep Quality Index is a self-report questionnaire that assesses sleep quality over a 1-month time interval. The measure consists of 19 individual items, creating 7 components that produce one global score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opiate consumption and analgesic medication consumption</measure>
    <time_frame>Screening to Day 100</time_frame>
    <description>Change in Opiate consumption and analgesic medication consumption</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression</measure>
    <time_frame>Baseline to Day 100</time_frame>
    <description>Change in Patient global impression. The Patient Global Impression is a 7 point scale depicting a patient's rating of overall improvement</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Low Back Pain</condition>
  <condition>Sciatica</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BOL-DP-o-04 + SCO</intervention_name>
    <description>sublingual drops</description>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo + SCO</intervention_name>
    <description>sublingual drops</description>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. &gt;18 years of age

          2. Mild to Severe Low Back Pain and/or Sciatica

          3. Imaging studies (CT or MRI) supporting anatomical abnormality that could be the cause
             of the symptoms

          4. Must be physically and mentally willing and able to comply with the treatment regimen
             and understand the informed consent and study procedures

          5. Signed and dated Informed Consent Form (ICF)

          6. Non-responsive to standard therapy for at least 1 month

        Exclusion Criteria:

          1. VAS Pain Subscale score at Screening is less than 6 (with 0 being no pain and 10 being
             worse imaginable pain)

          2. Known allergy to cannabis or its components

          3. A patient who is pregnant or intends to become pregnant during the study

          4. A patient who is nursing or intends to nurse during the study

          5. A patient suffering from a mental disorder precluding administration of study drug

          6. Prisoners

          7. A Patient is unable to sign an informed consent form

          8. Unstable angina pectoris

          9. Cardiac insufficiency precluding cannabis administration

         10. Immunosuppressed patients unless BOL-DP-o-04 administration is deemed safe by the
             treating physician

         11. Known Aspergillus infection

         12. Panic attacks or anxiety unless a psychiatrist allowed BOL-DP-o-04 following intake
             interview

         13. Any mental/psychiatric illness in first-degree relative in a young patient &lt;
             30-year-old.

         14. Patient with congestive heart failure

         15. Subjects who get the following medications: opiates, Primidone, Phenobarbitol,
             arbamazepine, Rifampicin, Rifabutin, Troglitazone, and Hypericum perforatum
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Eyal Heller, M.D.</last_name>
    <phone>+97239372233</phone>
    <email>eyalh@clalit.org.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beilinson Medical Center</name>
      <address>
        <city>Petach Pikva</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eyal Heller, M.D.</last_name>
      <phone>+97239372233</phone>
      <email>eyalh@clalit.org.il</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 29, 2019</study_first_submitted>
  <study_first_submitted_qc>October 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 30, 2019</study_first_posted>
  <last_update_submitted>October 30, 2019</last_update_submitted>
  <last_update_submitted_qc>October 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 31, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sciatica</mesh_term>
    <mesh_term>Back Pain</mesh_term>
    <mesh_term>Low Back Pain</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

